Herpes Cure Advocacy
@herpesadvocate.bsky.social
We are a grassroots membership-based, international advocacy organization with a goal of treatment, cure and prevention for Herpes Simplex Virus types 1 + 2.
www.herpescureadvocacy.com
www.herpescureadvocacy.com
Pinned
2024 HCA Annual Report
As we reflect on the past year, we are thrilled to share our 2024 Annual Report with you. This report offers a comprehensive look at the impact we’ve achieved together, the challenges we’ve faced, …
herpescureadvocacy.com
🌟 Our 2024 Annual Report is here! 🌟
Discover the milestones and impact we achieved together this past year. Thank you for being part of our journey!
herpescureadvocacy.com/2025/01/14/m...
Discover the milestones and impact we achieved together this past year. Thank you for being part of our journey!
herpescureadvocacy.com/2025/01/14/m...
📢 Upcoming Educational Webinar
How Clinicians and Patients Talk About Herpes: Bridging the Disconnect
Despite HSV’s prevalence, many patients face stigma, limited education, and gaps in care.
📅 March 5 | 5–6 PM EST
🔗 Register: us06web.zoom.us/meeting/regi...
How Clinicians and Patients Talk About Herpes: Bridging the Disconnect
Despite HSV’s prevalence, many patients face stigma, limited education, and gaps in care.
📅 March 5 | 5–6 PM EST
🔗 Register: us06web.zoom.us/meeting/regi...
Welcome! You are invited to join a meeting: Challenges in Clinical Care with Terri Warren. After registering, you will receive a confirmation email about joining the meeting.
Welcome! You are invited to join a meeting: Challenges in Clinical Care with Terri Warren. After registering, you will receive a confirmation email about joining the meeting.
us06web.zoom.us
February 11, 2026 at 3:44 AM
📢 Upcoming Educational Webinar
How Clinicians and Patients Talk About Herpes: Bridging the Disconnect
Despite HSV’s prevalence, many patients face stigma, limited education, and gaps in care.
📅 March 5 | 5–6 PM EST
🔗 Register: us06web.zoom.us/meeting/regi...
How Clinicians and Patients Talk About Herpes: Bridging the Disconnect
Despite HSV’s prevalence, many patients face stigma, limited education, and gaps in care.
📅 March 5 | 5–6 PM EST
🔗 Register: us06web.zoom.us/meeting/regi...
Phase 1B data presented by Dr. Grace Wang showed promising reductions in viral shedding and outbreaks for investigational long-acting HSV therapies.
Science is moving — and HSV research continues to progress.
youtu.be/MGhR42Ka2KM?...
#Virology
#LongActingTherapies
#MedicalScience
#EndTheStigma
Science is moving — and HSV research continues to progress.
youtu.be/MGhR42Ka2KM?...
#Virology
#LongActingTherapies
#MedicalScience
#EndTheStigma
Assembly Bio: Redefining the Treatment of Recurrent Genital Herpes Through Long-Acting Innovation
YouTube video by Herpes Cure Advocacy
youtu.be
February 11, 2026 at 1:55 AM
Phase 1B data presented by Dr. Grace Wang showed promising reductions in viral shedding and outbreaks for investigational long-acting HSV therapies.
Science is moving — and HSV research continues to progress.
youtu.be/MGhR42Ka2KM?...
#Virology
#LongActingTherapies
#MedicalScience
#EndTheStigma
Science is moving — and HSV research continues to progress.
youtu.be/MGhR42Ka2KM?...
#Virology
#LongActingTherapies
#MedicalScience
#EndTheStigma
🔴 DAY OF EVENT
TODAY is the day.
Join us for an exclusive scientific discussion with Assembly Bio on advancing long-acting treatments for recurrent genital herpes.
TODAY is the day.
Join us for an exclusive scientific discussion with Assembly Bio on advancing long-acting treatments for recurrent genital herpes.
Welcome! You are invited to join a meeting: Assembly Bio: Redefining the Treatment of Recurrent Genital Herpes Through Long-Acting Innovation.. After registering, you will receive a confirmation email...
Welcome! You are invited to join a meeting: Assembly Bio: Redefining the Treatment of Recurrent Genital Herpes Through Long-Acting Innovation.. After registering, you will receive a confirmation email...
us06web.zoom.us
February 5, 2026 at 11:15 AM
🔴 DAY OF EVENT
TODAY is the day.
Join us for an exclusive scientific discussion with Assembly Bio on advancing long-acting treatments for recurrent genital herpes.
TODAY is the day.
Join us for an exclusive scientific discussion with Assembly Bio on advancing long-acting treatments for recurrent genital herpes.
🚀 1 DAY BEFORE
Tomorrow.
We go deep into the science shaping the future of recurrent genital herpes treatment.
Join us for:
🧬 Clinical trial insights
💊 Long-acting therapy development
📈 Phase 2 outlook
Tomorrow.
We go deep into the science shaping the future of recurrent genital herpes treatment.
Join us for:
🧬 Clinical trial insights
💊 Long-acting therapy development
📈 Phase 2 outlook
Welcome! You are invited to join a meeting: Assembly Bio: Redefining the Treatment of Recurrent Genital Herpes Through Long-Acting Innovation.. After registering, you will receive a confirmation email...
Welcome! You are invited to join a meeting: Assembly Bio: Redefining the Treatment of Recurrent Genital Herpes Through Long-Acting Innovation.. After registering, you will receive a confirmation email...
us06web.zoom.us
February 4, 2026 at 11:49 PM
🚀 1 DAY BEFORE
Tomorrow.
We go deep into the science shaping the future of recurrent genital herpes treatment.
Join us for:
🧬 Clinical trial insights
💊 Long-acting therapy development
📈 Phase 2 outlook
Tomorrow.
We go deep into the science shaping the future of recurrent genital herpes treatment.
Join us for:
🧬 Clinical trial insights
💊 Long-acting therapy development
📈 Phase 2 outlook
🔬 2 DAYS BEFORE
In 48 hours, we’re talking about the real impact of recurrent genital herpes—and how science is working toward better solutions.
From epidemiology to patient experience to the next wave of antiviral development, this session is a must-attend.
In 48 hours, we’re talking about the real impact of recurrent genital herpes—and how science is working toward better solutions.
From epidemiology to patient experience to the next wave of antiviral development, this session is a must-attend.
Welcome! You are invited to join a meeting: Assembly Bio: Redefining the Treatment of Recurrent Genital Herpes Through Long-Acting Innovation.. After registering, you will receive a confirmation email...
Welcome! You are invited to join a meeting: Assembly Bio: Redefining the Treatment of Recurrent Genital Herpes Through Long-Acting Innovation.. After registering, you will receive a confirmation email...
us06web.zoom.us
February 3, 2026 at 12:41 PM
🔬 2 DAYS BEFORE
In 48 hours, we’re talking about the real impact of recurrent genital herpes—and how science is working toward better solutions.
From epidemiology to patient experience to the next wave of antiviral development, this session is a must-attend.
In 48 hours, we’re talking about the real impact of recurrent genital herpes—and how science is working toward better solutions.
From epidemiology to patient experience to the next wave of antiviral development, this session is a must-attend.
⏰ 3 DAYS BEFORE
3 days to go until we spotlight cutting-edge research in recurrent genital herpes.
Dr. Grace Wang, VP of Clinical Development at Assembly Biosciences, will present on:
• ABI-5366
• ABI-1179
• The future of long-acting HSV therapies
3 days to go until we spotlight cutting-edge research in recurrent genital herpes.
Dr. Grace Wang, VP of Clinical Development at Assembly Biosciences, will present on:
• ABI-5366
• ABI-1179
• The future of long-acting HSV therapies
Welcome! You are invited to join a meeting: Assembly Bio: Redefining the Treatment of Recurrent Genital Herpes Through Long-Acting Innovation.. After registering, you will receive a confirmation email...
Welcome! You are invited to join a meeting: Assembly Bio: Redefining the Treatment of Recurrent Genital Herpes Through Long-Acting Innovation.. After registering, you will receive a confirmation email...
us06web.zoom.us
February 2, 2026 at 4:06 PM
⏰ 3 DAYS BEFORE
3 days to go until we spotlight cutting-edge research in recurrent genital herpes.
Dr. Grace Wang, VP of Clinical Development at Assembly Biosciences, will present on:
• ABI-5366
• ABI-1179
• The future of long-acting HSV therapies
3 days to go until we spotlight cutting-edge research in recurrent genital herpes.
Dr. Grace Wang, VP of Clinical Development at Assembly Biosciences, will present on:
• ABI-5366
• ABI-1179
• The future of long-acting HSV therapies
New video: Herpes Cure Pipeline 4.0 (2025) 🎥
An in-depth look at emerging treatments, long-acting innovations, and scientific progress toward a cure for HSV.
Watch now:
youtube.com/watch?v=lGD6...
#HerpesCure #HSV #HerpesResearch #ClinicalTrials #CureForHerpes
An in-depth look at emerging treatments, long-acting innovations, and scientific progress toward a cure for HSV.
Watch now:
youtube.com/watch?v=lGD6...
#HerpesCure #HSV #HerpesResearch #ClinicalTrials #CureForHerpes
Herpes Cure Pipeline 4.0 2025
YouTube video by Herpes Cure Advocacy
youtube.com
January 29, 2026 at 12:30 AM
New video: Herpes Cure Pipeline 4.0 (2025) 🎥
An in-depth look at emerging treatments, long-acting innovations, and scientific progress toward a cure for HSV.
Watch now:
youtube.com/watch?v=lGD6...
#HerpesCure #HSV #HerpesResearch #ClinicalTrials #CureForHerpes
An in-depth look at emerging treatments, long-acting innovations, and scientific progress toward a cure for HSV.
Watch now:
youtube.com/watch?v=lGD6...
#HerpesCure #HSV #HerpesResearch #ClinicalTrials #CureForHerpes
Did you know that long-acting antiviral therapies are being developed to transform how recurrent genital herpes is treated?
On February 5th, we’re hosting Assembly Biosciences for a deep dive into:
🔬 Emerging long-acting HSV treatments
📊 Clinical trial findings
🧠 The future of patient care
On February 5th, we’re hosting Assembly Biosciences for a deep dive into:
🔬 Emerging long-acting HSV treatments
📊 Clinical trial findings
🧠 The future of patient care
Welcome! You are invited to join a meeting: Assembly Bio: Redefining the Treatment of Recurrent Genital Herpes Through Long-Acting Innovation.. After registering, you will receive a confirmation email...
Welcome! You are invited to join a meeting: Assembly Bio: Redefining the Treatment of Recurrent Genital Herpes Through Long-Acting Innovation.. After registering, you will receive a confirmation email...
us06web.zoom.us
January 28, 2026 at 11:53 PM
Did you know that long-acting antiviral therapies are being developed to transform how recurrent genital herpes is treated?
On February 5th, we’re hosting Assembly Biosciences for a deep dive into:
🔬 Emerging long-acting HSV treatments
📊 Clinical trial findings
🧠 The future of patient care
On February 5th, we’re hosting Assembly Biosciences for a deep dive into:
🔬 Emerging long-acting HSV treatments
📊 Clinical trial findings
🧠 The future of patient care
New HCA-Supported Research 🔬
Published in the International Journal of STD & AIDS, this study explores whether a history of genital herpes symptoms predicts HSV-2 antibody positivity.
Published in the International Journal of STD & AIDS, this study explores whether a history of genital herpes symptoms predicts HSV-2 antibody positivity.
Does genital herpes symptom history predict herpes simplex virus type 2 antibody positivity? - PubMed
With currently available tests, recommendations to screen individuals based on genital herpes symptom history may not be useful. More discriminatory symptom screening tools or HSV-2 antibody tests with better performance are needed.
pubmed.ncbi.nlm.nih.gov
January 21, 2026 at 11:26 PM
New HCA-Supported Research 🔬
Published in the International Journal of STD & AIDS, this study explores whether a history of genital herpes symptoms predicts HSV-2 antibody positivity.
Published in the International Journal of STD & AIDS, this study explores whether a history of genital herpes symptoms predicts HSV-2 antibody positivity.
New HCA-Supported Research 🧬
A review published in the Journal of the Pediatric Infectious Diseases Society analyzes how neonatal herpes is reported across U.S. states and reveals significant gaps and inconsistencies in current policies.
A review published in the Journal of the Pediatric Infectious Diseases Society analyzes how neonatal herpes is reported across U.S. states and reveals significant gaps and inconsistencies in current policies.
Neonatal Herpes Reporting in the United States: Review of Current Policies by State - PubMed
Despite its devastating impact, neonatal herpes is not a nationally notifiable condition. As of 2023 it is only reportable in 6 states. A consistently applied case definition with designation as a nationally notifiable condition would optimize surveillance and preventative efforts.
pubmed.ncbi.nlm.nih.gov
January 21, 2026 at 11:08 PM
New HCA-Supported Research 🧬
A review published in the Journal of the Pediatric Infectious Diseases Society analyzes how neonatal herpes is reported across U.S. states and reveals significant gaps and inconsistencies in current policies.
A review published in the Journal of the Pediatric Infectious Diseases Society analyzes how neonatal herpes is reported across U.S. states and reveals significant gaps and inconsistencies in current policies.
New HCA-Supported Research 📊
A recent study in Sexually Transmitted Diseases examines patterns of congenital syphilis in a large public hospital, highlighting key maternal risk factors and infant outcomes.
A recent study in Sexually Transmitted Diseases examines patterns of congenital syphilis in a large public hospital, highlighting key maternal risk factors and infant outcomes.
Patterns of Congenital Syphilis in a Large Public Hospital: Maternal Risk Factors and Infant Outcomes - PubMed
This case series identified maternal substance use and no prenatal care as risk factors for highly probable or possible CS, underscoring the vulnerability of this population and informing future work in prevention of this disease.
pubmed.ncbi.nlm.nih.gov
January 21, 2026 at 11:03 PM
New HCA-Supported Research 📊
A recent study in Sexually Transmitted Diseases examines patterns of congenital syphilis in a large public hospital, highlighting key maternal risk factors and infant outcomes.
A recent study in Sexually Transmitted Diseases examines patterns of congenital syphilis in a large public hospital, highlighting key maternal risk factors and infant outcomes.
New HCA-Supported Research 📄
We’re proud to highlight a new systematic review protocol examining the association between HSV-1 and dementia, published in BMJ Open.
We’re proud to highlight a new systematic review protocol examining the association between HSV-1 and dementia, published in BMJ Open.
Association between herpes simplex virus 1 and dementia: a systematic review protocol - PubMed
CRD42024516789.
pubmed.ncbi.nlm.nih.gov
January 17, 2026 at 1:02 AM
New HCA-Supported Research 📄
We’re proud to highlight a new systematic review protocol examining the association between HSV-1 and dementia, published in BMJ Open.
We’re proud to highlight a new systematic review protocol examining the association between HSV-1 and dementia, published in BMJ Open.
🔔Starting in 1 hour ⏳
From discovery to cure: the complex path of antiherpetic drug development
🎤 Luis Schang, MV, PhD
Join us live at 6pm EST.
🔗 us06web.zoom.us/meeting/regi...
From discovery to cure: the complex path of antiherpetic drug development
🎤 Luis Schang, MV, PhD
Join us live at 6pm EST.
🔗 us06web.zoom.us/meeting/regi...
Welcome! You are invited to join a meeting: HCA: From discovery to cure. After registering, you will receive a confirmation email about joining the meeting.
Welcome! You are invited to join a meeting: HCA: From discovery to cure. After registering, you will receive a confirmation email about joining the meeting.
us06web.zoom.us
January 13, 2026 at 9:59 PM
🔔Starting in 1 hour ⏳
From discovery to cure: the complex path of antiherpetic drug development
🎤 Luis Schang, MV, PhD
Join us live at 6pm EST.
🔗 us06web.zoom.us/meeting/regi...
From discovery to cure: the complex path of antiherpetic drug development
🎤 Luis Schang, MV, PhD
Join us live at 6pm EST.
🔗 us06web.zoom.us/meeting/regi...
🔔 DAY OF
Today’s the day.
From discovery to cure: the complex path of antiherpetic drug development
🎤 Luis Schang, MV, PhD
🕕 6:00pm EST
Last chance to register:
🔗 : us06web.zoom.us/meeting/regi...
Today’s the day.
From discovery to cure: the complex path of antiherpetic drug development
🎤 Luis Schang, MV, PhD
🕕 6:00pm EST
Last chance to register:
🔗 : us06web.zoom.us/meeting/regi...
Welcome! You are invited to join a meeting: HCA: From discovery to cure. After registering, you will receive a confirmation email about joining the meeting.
Welcome! You are invited to join a meeting: HCA: From discovery to cure. After registering, you will receive a confirmation email about joining the meeting.
us06web.zoom.us
January 13, 2026 at 2:34 PM
🔔 DAY OF
Today’s the day.
From discovery to cure: the complex path of antiherpetic drug development
🎤 Luis Schang, MV, PhD
🕕 6:00pm EST
Last chance to register:
🔗 : us06web.zoom.us/meeting/regi...
Today’s the day.
From discovery to cure: the complex path of antiherpetic drug development
🎤 Luis Schang, MV, PhD
🕕 6:00pm EST
Last chance to register:
🔗 : us06web.zoom.us/meeting/regi...
🔔 1 DAY OUT
Goal: Urgency
⏰ Tomorrow!
Join HCA for our first educational talk of 2026:
From discovery to cure: the complex path of antiherpetic drug development
🎤 Luis Schang, MV, PhD
🗓 Jan 13 | 6pm EST
Goal: Urgency
⏰ Tomorrow!
Join HCA for our first educational talk of 2026:
From discovery to cure: the complex path of antiherpetic drug development
🎤 Luis Schang, MV, PhD
🗓 Jan 13 | 6pm EST
Welcome! You are invited to join a meeting: HCA: From discovery to cure. After registering, you will receive a confirmation email about joining the meeting.
Welcome! You are invited to join a meeting: HCA: From discovery to cure. After registering, you will receive a confirmation email about joining the meeting.
us06web.zoom.us
January 12, 2026 at 2:56 PM
🔔 1 DAY OUT
Goal: Urgency
⏰ Tomorrow!
Join HCA for our first educational talk of 2026:
From discovery to cure: the complex path of antiherpetic drug development
🎤 Luis Schang, MV, PhD
🗓 Jan 13 | 6pm EST
Goal: Urgency
⏰ Tomorrow!
Join HCA for our first educational talk of 2026:
From discovery to cure: the complex path of antiherpetic drug development
🎤 Luis Schang, MV, PhD
🗓 Jan 13 | 6pm EST
🔔 3 DAYS OUT
Goal: Audience expansion + sharing
If you’re involved in research, healthcare, or advocacy around herpes, this is a session you won’t want to miss.
Goal: Audience expansion + sharing
If you’re involved in research, healthcare, or advocacy around herpes, this is a session you won’t want to miss.
Welcome! You are invited to join a meeting: HCA: From discovery to cure. After registering, you will receive a confirmation email about joining the meeting.
Welcome! You are invited to join a meeting: HCA: From discovery to cure. After registering, you will receive a confirmation email about joining the meeting.
us06web.zoom.us
January 10, 2026 at 6:59 PM
🔔 3 DAYS OUT
Goal: Audience expansion + sharing
If you’re involved in research, healthcare, or advocacy around herpes, this is a session you won’t want to miss.
Goal: Audience expansion + sharing
If you’re involved in research, healthcare, or advocacy around herpes, this is a session you won’t want to miss.
🔔 5 DAYS OUT!
In our upcoming HCA talk, Dr. Luis Schang will break down:
• Why “promising” therapies stall
• Where bottlenecks occur
• How antivirals like valacyclovir made it through — and why others struggle
🗓 Jan 13 | 6pm EST
🔗 Register: us06web.zoom.us/meeting/regi...
In our upcoming HCA talk, Dr. Luis Schang will break down:
• Why “promising” therapies stall
• Where bottlenecks occur
• How antivirals like valacyclovir made it through — and why others struggle
🗓 Jan 13 | 6pm EST
🔗 Register: us06web.zoom.us/meeting/regi...
Welcome! You are invited to join a meeting: HCA: From discovery to cure. After registering, you will receive a confirmation email about joining the meeting.
Welcome! You are invited to join a meeting: HCA: From discovery to cure. After registering, you will receive a confirmation email about joining the meeting.
us06web.zoom.us
January 8, 2026 at 4:34 PM
🔔 5 DAYS OUT!
In our upcoming HCA talk, Dr. Luis Schang will break down:
• Why “promising” therapies stall
• Where bottlenecks occur
• How antivirals like valacyclovir made it through — and why others struggle
🗓 Jan 13 | 6pm EST
🔗 Register: us06web.zoom.us/meeting/regi...
In our upcoming HCA talk, Dr. Luis Schang will break down:
• Why “promising” therapies stall
• Where bottlenecks occur
• How antivirals like valacyclovir made it through — and why others struggle
🗓 Jan 13 | 6pm EST
🔗 Register: us06web.zoom.us/meeting/regi...
We often hear about promising antiherpetic drugs… then nothing.
Why does that happen? Where are the bottlenecks?
Join HCA on Jan 13 at 6pm EST for a deep dive into the antiviral development pipeline with Luis Schang, MV, PhD — from lab discovery to clinical approval, with real HSV case studies.
Why does that happen? Where are the bottlenecks?
Join HCA on Jan 13 at 6pm EST for a deep dive into the antiviral development pipeline with Luis Schang, MV, PhD — from lab discovery to clinical approval, with real HSV case studies.
January 7, 2026 at 1:48 AM
We often hear about promising antiherpetic drugs… then nothing.
Why does that happen? Where are the bottlenecks?
Join HCA on Jan 13 at 6pm EST for a deep dive into the antiviral development pipeline with Luis Schang, MV, PhD — from lab discovery to clinical approval, with real HSV case studies.
Why does that happen? Where are the bottlenecks?
Join HCA on Jan 13 at 6pm EST for a deep dive into the antiviral development pipeline with Luis Schang, MV, PhD — from lab discovery to clinical approval, with real HSV case studies.
Research is advancing. Clinical trials are progressing.
A herpes cure is no longer a distant idea — it’s a real scientific pursuit.
A herpes cure is no longer a distant idea — it’s a real scientific pursuit.
December 20, 2025 at 11:28 PM
Research is advancing. Clinical trials are progressing.
A herpes cure is no longer a distant idea — it’s a real scientific pursuit.
A herpes cure is no longer a distant idea — it’s a real scientific pursuit.
We are closer to a herpes cure than ever before — and funding matters.
✨ Every gift fuels research awareness
✨ Every share fights stigma
✨ Every dollar brings us closer to a cure
Give hope before the year ends.
herpescureadvocacy.com/ways-to-give/
donatestock.com/herpes-cure-...
✨ Every gift fuels research awareness
✨ Every share fights stigma
✨ Every dollar brings us closer to a cure
Give hope before the year ends.
herpescureadvocacy.com/ways-to-give/
donatestock.com/herpes-cure-...
Ways to Give
Ways to Give At Herpes Cure Advocacy (HCA), we believe that every contribution, regardless of size, makes a meaningful difference in advancing our mission. We’ve made it easy for you to suppo…
herpescureadvocacy.com
December 20, 2025 at 11:27 PM
We are closer to a herpes cure than ever before — and funding matters.
✨ Every gift fuels research awareness
✨ Every share fights stigma
✨ Every dollar brings us closer to a cure
Give hope before the year ends.
herpescureadvocacy.com/ways-to-give/
donatestock.com/herpes-cure-...
✨ Every gift fuels research awareness
✨ Every share fights stigma
✨ Every dollar brings us closer to a cure
Give hope before the year ends.
herpescureadvocacy.com/ways-to-give/
donatestock.com/herpes-cure-...
Major update in HSV-2 research👇
Assembly Biosciences just released Phase 1b results showing:
• 91% fewer confirmed lesions
• 76–94% reduction in viral shedding
• 99%+ drop in high-viral-load samples
Assembly Biosciences just released Phase 1b results showing:
• 91% fewer confirmed lesions
• 76–94% reduction in viral shedding
• 99%+ drop in high-viral-load samples
December 9, 2025 at 6:06 PM
Major update in HSV-2 research👇
Assembly Biosciences just released Phase 1b results showing:
• 91% fewer confirmed lesions
• 76–94% reduction in viral shedding
• 99%+ drop in high-viral-load samples
Assembly Biosciences just released Phase 1b results showing:
• 91% fewer confirmed lesions
• 76–94% reduction in viral shedding
• 99%+ drop in high-viral-load samples
This #GivingTuesday, we’re fighting stigma and pushing for real progress toward an HSV cure.
Give today: herpescureadvocacy.com/ways-to-give/
Give today: herpescureadvocacy.com/ways-to-give/
Ways to Give
Ways to Give At Herpes Cure Advocacy (HCA), we believe that every contribution, regardless of size, makes a meaningful difference in advancing our mission. We’ve made it easy for you to suppo…
herpescureadvocacy.com
December 2, 2025 at 5:21 PM
This #GivingTuesday, we’re fighting stigma and pushing for real progress toward an HSV cure.
Give today: herpescureadvocacy.com/ways-to-give/
Give today: herpescureadvocacy.com/ways-to-give/
Did you miss our #herpesawarenessday talk on better testing for #herpes? We have it recorded and you can find it and all our other educational talks on our website under Recorded Talks! Have a topic you're interested in learning more of? Let us know!
herpescureadvocacy.com/recorded-tal...
herpescureadvocacy.com/recorded-tal...
Recorded Talks
Herpes Cure Advocacy hosts monthly meetings covering a wide range of HSV related topics. We understand not everyone is able to attend the talks live, so we’ve created this page as a resource …
herpescureadvocacy.com
October 23, 2025 at 2:34 AM
Did you miss our #herpesawarenessday talk on better testing for #herpes? We have it recorded and you can find it and all our other educational talks on our website under Recorded Talks! Have a topic you're interested in learning more of? Let us know!
herpescureadvocacy.com/recorded-tal...
herpescureadvocacy.com/recorded-tal...